Oral oncology最新文献

{"title":"Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies","authors":"Jiaqian Wu, Jianning Zhang, Jiachuan Lin, Yan Huo","doi":"10.1016/j.oraloncology.2025.107812","DOIUrl":"10.1016/j.oraloncology.2025.107812","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107812"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer","authors":"Sholem Hack ,&nbsp;Rebecca Attal ,&nbsp;Karin Geva ,&nbsp;Armin Farzad ,&nbsp;Shibli Alsleibi ,&nbsp;Naseem Saleh ,&nbsp;Ben Gvili ,&nbsp;David Yogev ,&nbsp;David Shahal ,&nbsp;Benyamin Meir Kaminer ,&nbsp;Eric Remer","doi":"10.1016/j.oraloncology.2025.107813","DOIUrl":"10.1016/j.oraloncology.2025.107813","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the quality of online information about human papillomavirus (HPV)–associated oropharyngeal cancer generated by a large language model with content retrieved from conventional web search and authoritative guideline-based sources.</div></div><div><h3>Methods</h3><div>Twenty high-volume patient search queries were identified using global Google Trends data. For each question, responses were obtained from GPT-4 (OpenAI), the highest-ranked non-sponsored Google Search result, and leading governmental or guideline-based websites. Responses were anonymized and evaluated in a blinded manner by seven otolaryngology specialists and ten adult laypersons. Experts assessed accuracy, clarity, completeness, relevance, and usefulness; laypersons rated clarity, trustworthiness, and usefulness. Comparative analyses were performed using Friedman and Bonferroni-corrected Wilcoxon signed-rank tests, with inter-rater agreement estimated using intraclass correlation coefficients (ICC)</div></div><div><h3>Results</h3><div>ChatGPT-generated responses received higher mean ratings than Google Search across all domains for both rater cohorts (p &lt; 0.001 for all comparisons). Experts rated GPT-4 and guideline-based content similarly for accuracy, completeness, and usefulness, while GPT-4 scored significantly higher for clarity and relevance (p &lt; 0.01). Laypersons rated GPT-4 responses highest across all domains, with median scores of 5 versus 4 for the other sources. Inter-rater agreement was modest for subjective domains.</div></div><div><h3>Conclusion</h3><div>ChatGPT-generated information on HPV-associated oropharyngeal cancer matched the accuracy and completeness of authoritative guideline-based content and demonstrated significantly greater clarity and relevance, while outperforming conventional web search results. LLMs may help improve accessibility and consistency of online patient education when implemented with expert oversight, transparent sourcing, and ongoing quality monitoring.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107813"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is 55 years an optimal age cutoff point for clinical staging in T1 papillary thyroid cancer?","authors":"Daixing Hu ,&nbsp;Zhuolin Dai ,&nbsp;Yang Feng ,&nbsp;Xinliang Su ,&nbsp;Chun Huang","doi":"10.1016/j.oraloncology.2025.107817","DOIUrl":"10.1016/j.oraloncology.2025.107817","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to determine the optimal age cutoff for T1 papillary thyroid cancer (PTC), with a particular focus on the T1a and T1b subgroups.</div></div><div><h3>Methods</h3><div>A retrospective review of electronic medical records was conducted to identify patients who underwent thyroidectomy at our institution from January 2013 to December 2018.</div></div><div><h3>Results</h3><div>The study cohort consisted of 2,862 patients, including 765 men (26.7 %) and 2,097 women (73.3 %). Survival analysis demonstrated significantly poorer recurrence-free survival (RFS) in patients aged ≥55 years (p &lt; 0.001). Patients were stratified into T1 (tumor size ≤2 cm, n = 2,328) and non-T1 (tumor size &gt;2 cm, n = 534) subgroups. Among the non-T1 subgroup, older patients exhibited significantly inferior RFS, consistent with the overall cohort (p &lt; 0.001). However, this difference was not observed in the T1 subgroup (p = 0.079). Within the T1 PTC subgroup, significant differences were identified between T1a and T1b patients concerning gender distribution, tumor size, clinical lymph node-positive status (cN1), total thyroidectomy, bilaterality, presence of Hashimoto’s thyroiditis, central lymph node metastasis, lateral lymph node metastasis, and radioiodine treatment (all p &lt; 0.05). Further analysis indicated that when stratified by an age cutoff of 65 years, the prognosis for T1b patients was statistically significant (p = 0.018), whereas the prognosis for T1a patients was not statistically significant (p = 0.64).</div></div><div><h3>Conclusion</h3><div>The clinicopathologic characteristics of T1b patients differ significantly from those of T1a patients. Age may not be a critical factor in the prognostic staging system for T1a PTC patients, whereas 65 years appears to be a more appropriate age cutoff for T1b patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107817"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrovascular events after head and neck radiation therapy: A systematic review and Meta-Analysis","authors":"Kennedy Ayoo ,&nbsp;Elliot Koo ,&nbsp;Noémie Villemure-Poliquin ,&nbsp;Rui Fu ,&nbsp;Jonathan C Irish ,&nbsp;Thomas Lindsay ,&nbsp;Antoine Eskander","doi":"10.1016/j.oraloncology.2025.107810","DOIUrl":"10.1016/j.oraloncology.2025.107810","url":null,"abstract":"<div><h3>Background</h3><div>Several studies have demonstrated increased risk of cerebrovascular events, including carotid stenosis, stroke &amp; transient ischemic attack, following head and neck radiation therapy (RT) for head and neck cancer (HNC). This systematic review reports the incidence of cerebrovascular events (CVEs) and the relative rate (RR) of ischemic stroke in patients treated with RT compared to non-RT populations.</div></div><div><h3>Methods</h3><div>A comprehensive database search identified publications reporting the incidence or RR of CVEs following RT. Citations were retrieved, and data was extracted where appropriate. Risk of bias was assessed, and <em>meta</em>-analyses were conducted to present pooled estimates of the incidence of CVEs after RT and the RR of ischemic stroke.</div></div><div><h3>Results</h3><div>2,598 citations were retrieved, of which 50 met criteria for inclusion. The incidence of carotid stenosis ranged from 0 %-40 % over median follow-up duration of 6–68 months (mean = 6–150 months). The incidence of ischemic stroke was 8.98 per 1,000 person-years (95 % CI: 4.66 – 17.30). The relative rate of ischemic stroke was higher in patients treated with radiation therapy with a HR of 1.33 (95 % CI: 1.21 – 1.45) when compared to a reference population (HR of 1) of those treated with surgery and a HR of 1.29 (95 % CI: 1.13 – 1.47) when compared to the general population as the reference group.</div></div><div><h3>Conclusions</h3><div>HNC patients face an increased risk of ischemic stroke following head and neck radiation therapy. The magnitude of this heightened risk remains elusive in the contemporary era of intensity-modulated radiation techniques and should be addressed in future studies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107810"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival rates and oncologic outcomes of adeno squamous carcinoma of oral cavity: A systematic review","authors":"Francesco Chiari ,&nbsp;Andrea Luigi Camillo Carobbio ,&nbsp;Marco Ferrari ,&nbsp;Piero Nicolai ,&nbsp;Claudio Donadio Caporale ,&nbsp;Pierre Guarino","doi":"10.1016/j.oraloncology.2025.107821","DOIUrl":"10.1016/j.oraloncology.2025.107821","url":null,"abstract":"<div><h3>Background</h3><div>Adenosquamous carcinoma (ASC) of the oral cavity is an uncommon and aggressive malignancy characterized by squamous and glandular histologic components. Due to its rarity, clinical behavior and oncologic outcomes remain poorly defined.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted according to PRISMA 2020 guidelines. Comprehensive searches of Embase, PubMed, Scopus, and Cochrane Library identified studies published between 1968 and 2025.</div></div><div><h3>Results</h3><div>Sixty-one patients were included. The most frequent subsites were tongue (43 %) and floor of mouth (31 %). Transoral surgery was performed in 93 % of cases, with neck dissection in 50 %. Adjuvant therapy was administered in 27 %. Despite 57 % presenting with early-stage disease, recurrence occurred in 42 %: local (36 %), regional (20 %), and distant (10 %). Local recurrence was significantly associated with advanced stage (p = 0.007) and subsite (p = 0.028), highest in floor of mouth (59 %) and gingiva (50 %). Perineural invasion (PNI), lymphovascular invasion (LVI), and positive margins correlated with recurrence and reduced time to recurrence (TTR), disease-specific survival (DSS), and overall survival (OS) (p &lt; 0.001). Two-year TTR, DSS, and OS rates were 47 %, 74 %, and 70 %, respectively—lower than reported for conventional oral squamous carcinoma. Because oral ASC is rare, the evidence is primarily derived from case reports and small retrospective series.</div></div><div><h3>Conclusions</h3><div>Oral ASC demonstrates high recurrence and poor survival, even in early-stage disease. Prognosis is strongly influenced by PNI, LVI, and margin status, as well as tumor subsite. These findings highlight oral ASC as a distinct and particularly aggressive entity.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107821"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145757122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrathyroid thymic carcinoma diagnosed following an odontogenic infection: Insights from a rare clinical presentation","authors":"Hitoshi Miyashita ,&nbsp;Haruka Saito ,&nbsp;Masashi Katoh ,&nbsp;Fumiyoshi Fujishima ,&nbsp;Nobuo Ohta","doi":"10.1016/j.oraloncology.2025.107797","DOIUrl":"10.1016/j.oraloncology.2025.107797","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107797"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145617265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and characterization of a new immortalized human oral keratinocyte (HOK) cell line harboring various TP53 mutations","authors":"Mei Zhao ,&nbsp;Zhiyi Liu ,&nbsp;Mutsuki Kawabe ,&nbsp;Abdullah A Osman ,&nbsp;Mitchell J. Frederick ,&nbsp;Jeffrey N Myers","doi":"10.1016/j.oraloncology.2025.107799","DOIUrl":"10.1016/j.oraloncology.2025.107799","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) is characterized by frequent<!--> <em>TP53</em> <!-->mutations, which include gain-of-function (GOF) variants that drive tumor progression and chemoresistance. While genomic evidence across multiple specimens ranging from oral pre-malignant lesions (OPL) through invasive and metastatic HNSCC indicates that <em>TP53</em> loss or mutation occurs relatively early in HNSCC carcinogenesis, it has been difficult to discern how mutation of this tumor suppressor drives further tumor cell evolution and influences the tumor microenvironment to drive tumor progression. To address this question, we generated an immortalized human oral keratinocyte (iHOK) cell line expressing wt <em>TP53</em> as well as <em>TP53</em> mutant forms to determine how mutations impact functional and genomic characteristics of HOKs that can in turn drive their evolution to neoplastic cells.</div><div>We established a novel panel of iHOK cell lines harboring distinct<!--> <em>TP53</em> <!-->mutations, including the high-risk C238F variant. Key results revealed significant phenotypic and molecular divergence: high-risk lines exhibited enhanced invasiveness and chemoresistance compared to low-risk counterparts. Weighted gene co-expression network analysis (WGCNA) linked high-risk mutations to pro-metastatic pathways and stress-response signatures, with the C238F line uniquely enriched for p53-related GOF mechanisms. Conversely, low-risk lines remained chemosensitive.</div><div>These findings underscore the clinical relevance of mutation-specific iHOK models in determining the transcriptomic events that drive invasiveness and drug resistance and identify ways to intercept these phenotypes. By mirroring the<!--> <em>TP53</em> <!-->diversity observed in patient tumors, this cell line panel bridges a critical gap in head and neck carcinogenesis research, enabling mechanistic dissection of GOF phenotypes and preclinical evaluation of therapies in an array of <em>TP53</em> <!-->mutant cell models. Its significance lies in providing a validated, annotated resource that accelerates drug discovery and clarifies the role of<!--> <em>TP53</em> <!-->mutational subtypes in HNSCC development and progression, offering a framework for future translational studies in genetically complex malignancies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107799"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145617263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR","authors":"A. Hafström ,&nbsp;E. Hammerlid ,&nbsp;M. Beran ,&nbsp;M. Olin ,&nbsp;A. Högmo ,&nbsp;L. Farnebo","doi":"10.1016/j.oraloncology.2025.107818","DOIUrl":"10.1016/j.oraloncology.2025.107818","url":null,"abstract":"<div><h3>Background and importance</h3><div>The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.</div></div><div><h3>Methods</h3><div>This is a nation-wide, population-based study of treatment and outcome from prospectively recorded data for 2,111 vlSCC registered in the Swedish Head and Neck Cancer Register (SweHNCR) diagnosed 2008–2022.</div></div><div><h3>Results</h3><div>The age standardized incidence increased with 34 % between 2008 and 2022, from 1.14 to 1.53 per 100,000 (19 % for males and 55 % for females). Median age at diagnosis was 76 years and 72.4 % had good performance status. Males predominated (57.1 %). Lower lip vlSCC comprised 82.6 % and upper 8.6 %. Most had T1 (81.7 %) or T2 (13.5 %) tumors and few had regional (2.7 %) or distant (0.1 %) metastases. The 5-year observed overall survival was 70.5 % (95 % CI 68.4–72.6) and relative survival 90.8 % (95 % CI 88.2–93.7).</div><div>Treatment data were registered in 1,948 cases and 97.5 % (1,900) had a curative intent, whereof 88.5 % had surgery, 7.3 % radiotherapy, and 4.2 % combination treatment. Recurrences were registered in 5.6 % (48.6 % local, 42.1 % regional) whereof 15.9 % after three years. Stage I recurred after median 17 (IQR 9–28) months whereas stage II and III after 10 months (7–17 and 9–13, respectively). Advanced age (p &lt; 0.001), poor performance status (p &lt; 0.001), male sex (p = 0.002), high stage (p = 0.041), and only radiotherapy (p = 0.007) remained as independent prognostic factors for mortality.</div></div><div><h3>Conclusion</h3><div>Females had higher incidence increase than males. Advanced age, poor performance status, male sex, advanced disease, and radiotherapy only were independent prognostic factors for mortality.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107818"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial","authors":"Wen-Jie Wu ,&nbsp;Pu-Gen An ,&nbsp;Zi-Qi Zhang ,&nbsp;Li-Hang Shen ,&nbsp;Jian-Yun Zhang ,&nbsp;Yan Chen ,&nbsp;Ming-Wei Huang ,&nbsp;Shu-Ming Liu ,&nbsp;Jie Yao ,&nbsp;Jie Zhang","doi":"10.1016/j.oraloncology.2025.107809","DOIUrl":"10.1016/j.oraloncology.2025.107809","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to evaluate the antitumor effect and safety of neoadjuvant chemotherapy plus tislelizumab (a programmed death-1 inhibitor) for the treatment of resectable locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC).</div></div><div><h3>Methods</h3><div>Eligible patients with stage III-IV LAOOPSCC were treated with two cycles of tislelizumab (200 mg), albumin-bound paclitaxel (260 mg/m²), and cisplatin (60–75 mg/m²) with a three-week interval between each cycle; this treatment was followed by surgery and adjuvant radiotherapy or concurrent chemoradiotherapy. The primary endpoints were the major pathological response (MPR) rate and safety.</div></div><div><h3>Results</h3><div>Between March 2022 and June 2023, a total of 82 patients were eligible and completed two cycles of neoadjuvant therapy; 78 patients underwent imaging evaluation, and 73 underwent surgery and pathological response evaluation. Forty patients underwent de-escalation surgery for the primary tumor. Orbital floor resection was avoided in 1 patient, mandibulectomy was avoided in 5 patients, and near-total glossectomy or total glossectomy was avoided in 32 patients. An objective response rate of 67.9 % and an MPR rate of 60.3 % were achieved, with 34.2 % of patients achieving a pathological complete response. With a median follow-up time of 24 months, the two-year overall survival rate was 84.4 %, and the two-year event-free survival rate was 76.7 %. Treatment-related adverse events of grade 3 or 4 occurred in 11 patients (13.4 %) during the neoadjuvant therapy.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant tislelizumab plus chemotherapy for LAOOPSCC achieved a high pathological response rate and favorable survival metrics with an acceptable safety profile.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107809"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer","authors":"Velda Ling-Yu CHOW,&nbsp;Valerie Wai-Yee HO,&nbsp;Arthur Shing-Ho LO","doi":"10.1016/j.oraloncology.2025.107819","DOIUrl":"10.1016/j.oraloncology.2025.107819","url":null,"abstract":"<div><h3>Background</h3><div>A report on the feasibility of sequential robotic-assisted neck dissection and robotic micro-surgical free flap reconstruction via a <em>trans</em>-hairline approach in oral cavity cancer patients.</div></div><div><h3>Material and methods</h3><div>A patient with cT2N0 right tongue squamous cell carcinoma is used for illustration.</div></div><div><h3>Results</h3><div>A <em>trans</em>-hairline incision is used. Subplatysmal flaps are raised and levels I-III cervical lymph nodes are exposed. Da Vinci Xi robotic system is then docked via <em>trans</em>-hairline incision for neck dissection followed by <em>trans</em>-oral hemi-glossectomy. Skin island of free anterolateral thigh flap is used to reconstruct intra-oral mucosal defect. Flap pedicle is passed to the neck medial to mandible for microvascular anastomosis using the Symani micro-robotic surgical system via <em>trans</em>-hairline incision.</div></div><div><h3>Conclusion</h3><div>Trans-hairline robotic-assisted neck dissection and robotic microvascular free flap surgery is feasible and safe with good cosmetic and functional outcomes in oral cavity cancer patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107819"},"PeriodicalIF":3.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}